FLEMINGTON, N.J., May 5, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today announced that abstracts outlining two, separate ongoing Phase I clinical trials evaluating its investigational lead compound onapristone have been accepted for poster presentation at the upcoming 50th American Society of Clinical Oncology (ASCO) Annual Meeting, being held May 30 – June 3, 2014 in Chicago, Illinois.
Arno will present the objectives, methods and study designs for its two ongoing studies evaluating targeted therapy onapristone, including the Phase I trial in women with progesterone receptor expressing tumors and the Phase I/II trial in men with advanced castration-resistant prostate cancer (CRPC), who have failed treatment with abiraterone or enzalutamide.
The list of abstracts and timing of the presentations is provided below.
- A randomized, parallel-dose phase 1 study of onapristone (ONA) in patients (pts) with progesterone receptor (PR)-expressing cancer
First / Presenting Author: Paul H. Cottu, MD, MSc; Institut Curie, France
General Poster Session: Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Date, Location: Sunday, June 1, 8:00 AM - 11:45 AM; S Hall A2
- A phase 1-2 study of the type I progesterone receptor (PR) antagonist onapristone (ONA) in patients (pts) with advanced castration-resistant prostate cancer (CRPC)
First / Presenting Author: Joaquin Mateo, MD; The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, United Kingdom
General Poster Session: Genitourinary (Prostate) Cancer
Date, Location: Monday, June 2, 1:15 PM - 5:00 PM; S Hall A2
Glenn Mattes, President and Chief Executive Officer of Arno Therapeutics, said, "The abstracts accepted for poster presentation at this year's ASCO meeting are a testament to the strides we have made to advance our strategic clinical development plan for onapristone. We continue to actively enroll patients in two Phase I trials to evaluate this oral anti-progestin, which has the potential to be a first-in-class compound approved for oncology indications and provide chemotherapy-sparing treatment to cancer patients who express a specific biomarker. We are excited by the momentum generated thus far and look forward to discussing further at the Annual Meeting."
Onapristone is an oral anti-progestin that has been shown in previous Phase II clinical trials to exhibit anti-tumor activity in patients with breast cancer. In pre-clinical testing, onapristone has been shown to block the activation of the progesterone receptor (PR), which is believed to be a mechanism that inhibits the growth of breast, endometrial and other tumors driven by aberrant function of the PR. Tests for the activated form of the progesterone receptor (APR) have the potential to function as a biomarker of anti-progestin activity, as detected by a companion diagnostic currently under development.
About Arno Therapeutics
Arno Therapeutics is a clinical stage biopharmaceutical company developing innovative products for the treatment of cancer. Arno has exclusive worldwide rights to develop and market three innovative anti-cancer product candidates. These compounds are in clinical or preclinical development as product candidates to treat hematologic malignancies and solid tumors. For more information about the company, please visit www.arnothera.com.
This press release contains forward-looking statements that involve substantial risks and uncertainties. These statements are often, but not always, made through the use of words or phrases such as "anticipates," "expects," "plans," "believes," "intends," and similar words or phrases. These forward-looking statements include, without limitation, statements regarding the timing, progress and anticipated results of the clinical development of onapristone, statements regarding the potential of onapristone as a treatment for breast, prostate and other cancers, statements regarding Arno's use and development of a diagnostic test to identify patients with APR tumors, as well as Arno's strategy, future operations, outlook, milestones, future financial position, future financial results, plans and objectives. We may not actually achieve these plans, intentions or expectations and Arno cautions investors not to place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Various important factors could cause actual results or events to differ materially from the forward-looking statements that we make. Such factors include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of onapristone or any of our other product candidates, our ability to successfully develop a diagnostic to identify APR tumors, our ability to finance the development of our product candidates, regulatory risks, and our reliance on third party researchers and other collaborators. Additional risks are described in the company's Annual Report on Form 10-K for the year ended December 31, 2013. Arno is providing this information as of the date of this press release and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.
CONTACT: The Ruth Group Lee Roth (investors) firstname.lastname@example.org (646) 536-7012 Kirsten Thomas (media) email@example.com (646) 536-7014 Arno Therapeutics Glenn Mattes firstname.lastname@example.org (862) 703-7176
Source:Arno Therapeutics Inc.